Telehealth Startup Virta Health Releases First Year Results of Type II Diabetes Study
Nutrition and diabetes management telehealth startup Virta Health, launched last March, has announced the publication of the 1-year results of its clinical trial. The app seeks to treat type 2 diabetes through close patient monitoring and guidance on a low carbohydrate diet, and has previously been found effective in reversing the advancement of the disease in short periods. However, the new results are the first source of data addressing the long-term efficacy of the program.
The study augments Virta Health’s existing body of peer-reviewed research, which proved that the Virta Treatment could systematically reverse type 2 diabetes in as little as 10 weeks. Newly released data demonstrates that diabetes reversal rates are sustained and in fact improved at one year, while metrics of other chronic conditions, such as obesity, blood pressure, cardiovascular disease and inflammation, are also substantially improved.
“What’s exciting about this new data is both the sustainability of the outcomes and the improvements in other comorbidities, such as high blood pressure, inflammation and heart disease,” said Sami Inkinen, CEO and Co-Founder of Virta Health. “I am more excited than ever about what this means for our current and future patients, not to mention the impact we can make on the economic burden of chronic disease as we scale towards our long-term goal of reversing type 2 diabetes in 100 million people by 2025.”
Virta’s solution is designed to provide patients with constant access to care providers while using telehealth technologies to ensure the program’s scalability.
Virta’s continuous remote care model—near real-time access to physicians and other clinical team members via a mobile device—reinvents diabetes treatment to allow for scale to millions of people. Enterprises, such as Virta customer Purdue University, are benefitting too by promoting a healthier workforce and experiencing significant savings for each employee receiving the Virta Treatment.
Some of the highlights from the study results:
• 60 percent of those completing one year had type 2 diabetes reversed (HbA1c < 6.5% while taking no glycemic control medications or only metformin).
• 83 percent remained enrolled in the trial.
• 94 percent of insulin users reduced or stopped usage altogether.
• Participants experienced 1.3 percent average reduction in HbA1c (while reducing or eliminating medications).
• Participants achieved 12 percent weight loss on average.